54 related articles for article (PubMed ID: 24117654)
21. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.
Wiegand SB; Heidrich B; Susser S; Rogalska-Taranta M; Petersen J; Böker KH; Grigorian N; Link R; Naumann U; John C; Lueth S; Malfertheiner P; Manns MP; Wedemeyer H; Sarrazin C; Cornberg M
PLoS One; 2015; 10(12):e0145622. PubMed ID: 26699619
[TBL] [Abstract][Full Text] [Related]
22. IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders.
Calisti G; Tavares A; Macartney MJ; McCormick A; Labbett W; Jacobs M; Dusheiko G; Rosenberg WM; Haque T
Springerplus; 2015; 4():357. PubMed ID: 26191484
[TBL] [Abstract][Full Text] [Related]
23. Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients.
Fathy MM; Abo Taleb ME; El Hawary MS; Nabih MI; Aref WM; Makhlouf MM
Cytokine; 2015 Aug; 74(2):268-72. PubMed ID: 26003758
[TBL] [Abstract][Full Text] [Related]
24. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
[TBL] [Abstract][Full Text] [Related]
25. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.
Fujino H; Imamura M; Nagaoki Y; Kawakami Y; Abe H; Hayes CN; Kan H; Fukuhara T; Kobayashi T; Masaki K; Ono A; Nakahara T; Honda Y; Naeshiro N; Urabe A; Yokoyama S; Miyaki D; Murakami E; Kawaoka T; Hiraga N; Tsuge M; Hiramatsu A; Hyogo H; Aikata H; Takahashi S; Miki D; Ochi H; Ohishi W; Chayama K;
J Gastroenterol; 2014 Dec; 49(12):1548-56. PubMed ID: 24362944
[TBL] [Abstract][Full Text] [Related]
26. The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection.
Covolo L; Bibert S; Donato F; Bochud PY; Lagging M; Negro F; Fattovich G
Aliment Pharmacol Ther; 2014 Feb; 39(3):322-30. PubMed ID: 24308755
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C.
Kondo C; Atsukawa M; Tsubota A; Shimada N; Abe H; Aizawa Y
J Postgrad Med; 2016; 62(1):20-5. PubMed ID: 26732192
[TBL] [Abstract][Full Text] [Related]
28. Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.
About F; Oudot-Mellakh T; Niay J; Rabiéga P; Pedergnana V; Duffy D; Sultanik P; Cagnot C; Carrat F; Marcellin P; Zoulim F; Larrey D; Hézode C; Fontaine H; Bronowicki JP; Pol S; Albert ML; Theodorou I; Cobat A; Abel L;
PLoS One; 2015; 10(12):e0145105. PubMed ID: 26670100
[TBL] [Abstract][Full Text] [Related]
29. Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection.
Kanda T; Nakamoto S; Nakamura M; Jiang X; Miyamura T; Wu S; Yokosuka O
J Clin Transl Hepatol; 2014 Mar; 2(1):1-6. PubMed ID: 26356295
[TBL] [Abstract][Full Text] [Related]
30. Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks.
Tamai H; Shimizu R; Shingaki N; Mori Y; Maeshima S; Nuta J; Maeda Y; Moribata K; Muraki Y; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Ichinose M
Hepat Res Treat; 2014; 2014():748935. PubMed ID: 25328696
[TBL] [Abstract][Full Text] [Related]
31. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.
Liu CH; Kao JH
Int J Nanomedicine; 2014; 9():2051-67. PubMed ID: 24812506
[TBL] [Abstract][Full Text] [Related]
32. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
33. Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.
Shimada N; Toyoda H; Tsubota A; Ide T; Takaguchi K; Kato K; Kondoh M; Matsuyama K; Kumada T; Sata M
J Gastroenterol; 2014 Nov; 49(11):1485-94. PubMed ID: 24287582
[TBL] [Abstract][Full Text] [Related]
34. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.
Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Hsu SJ; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2012; 17(3):477-84. PubMed ID: 22301466
[TBL] [Abstract][Full Text] [Related]
35. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis.
Bota S; Sporea I; Şirli R; Neghină AM; Popescu A; Străin M
Clin Drug Investig; 2013 May; 33(5):325-31. PubMed ID: 23532802
[TBL] [Abstract][Full Text] [Related]
36. Host factors determining the efficacy of hepatitis C treatment.
Chuang WL; Yu ML
J Gastroenterol; 2013 Jan; 48(1):22-30. PubMed ID: 23104468
[TBL] [Abstract][Full Text] [Related]
37. Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b.
Tsubota A; Shimada N; Atsukawa M; Abe H; Kato K; Ika M; Matsudaira H; Nagatsuma K; Matsuura T; Aizawa Y
J Gastroenterol Hepatol; 2014 Jan; 29(1):144-50. PubMed ID: 24117654
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
